Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total knee replacement: a randomized enoxaparin-controlled open label dose-escalation study.

Trial Profile

Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total knee replacement: a randomized enoxaparin-controlled open label dose-escalation study.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2011

At a glance

  • Drugs Darexaban; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions
  • Acronyms PEARL-1
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 May 2009 Actual patient number (367) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top